Bidding for Onyx Pharma (ONXX) Done? Not Likely...
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Novartis (NVS), Pfizer (PFE) Out on Onyx (ONXX); Is Amgen (AMGN) the Sole Runner?
August 13, 2013 3:23 PM EDTOnyx Pharma (Nasdaq: ONXX) shares dropped down for a second time today on this roller coaster Tuesday.
First, the stock got a boost following comments from Novartis (NYSE: NVS) chairman Joerg Reinhardt, who... More
Brean Capital Boosts Onyx Pharma (ONXX) Price Target to $160
July 1, 2013 2:41 PM EDTBrean Capital today maintained a Buy rating on Onyx Pharmaceuticals (NASDAQ: ONXX) and raised its price target to $160.00 (from $115.00). The change follows news Onyx Pharmaceuticals received an unsolicited bid from Amgen Inc. (Nasdaq: AMGN).
"Our $115... More
Maxim Group Downgrades Onyx Pharmaceuticals (ONXX) to Hold
July 1, 2013 11:18 AM EDTMaxim Group downgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to Hold.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $86.82 yesterday, with a 52 week range of $63.00-$101.57.... More
Onyx Pharma (ONXX) Reports $120/Share Bid from Amgen (AMGN); Hires Advisor
July 1, 2013 6:24 AM EDTOnyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today confirmed that it has received and rejected an unsolicited proposal from Amgen Inc. (Nasdaq: AMGN) to acquire all of Onyx's outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions. The Board of Directors of Onyx had evaluated the proposal made by Amgen with the assistance of its financial and legal advisors and concluded that... More
